Search clinical trials for: ONTAK (denileukin difitox, DAB389IL-2)

Total 96 results

Eisai Inc.
National Cancer Institute (NCI); Tufts Medical Center; Ligand Pharmaceuticals

Completed

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Lymphoma, T-Cell, Cutaneous

United States
University of Washington
National Cancer Institute (NCI)

Completed

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Barbara Ann Karmanos Cancer Institute
Eisai Inc.

Terminated

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Eisai Inc.

No longer available

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Cancer
National Cancer Institute (NCI)

Terminated

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Leukemia, Adult T-Cell

United States
Eisai Inc.

Completed

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Lymphoma, B-Cell

United States
The University of Texas Health Science Center at...

Completed

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (ONTAK)

Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal Cancer

United States
M.D. Anderson Cancer Center

Completed

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

Leukemia | Systemic Mastocytosis

United States
James Graham Brown Cancer Center
University of Louisville

Completed

Phase II Trial of Ontak With Metastatic Melanoma

Malignant Melanoma

United States
Loyola University
Eisai Inc.; Riveria Country Club Organization

Terminated

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
The University of Texas Health Science Center at...

Terminated

A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer

Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Kidney Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Leukemia

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Kidney Cancer | Melanoma (Skin)

United States
Eisai Co., Ltd.

Completed

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma

Japan
Pharmatech Oncology

Unknown

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
Columbia University

Withdrawn

Denileukine Diftitox for Relapsed ALCL

Anaplastic Large-Cell Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Ovarian Germ Cell Tumor

United States
University Hospital Erlangen

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

Germany
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
H. Kim Lyerly
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Withdrawn

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells (CLONTAK)

CHRONIC LYMPHOCYTIC B-LEUKEMIA
Eisai Inc.

Completed

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Lymphoma, T-cell, Peripheral | Lymphoma, T-cell, Cutaneous

Japan
Masonic Cancer Center, University of Minnesota

Terminated

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Leukemia, Myelogenous, Acute

United States
Ligand Pharmaceuticals

Completed

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Lymphoma | Drug/Agent Toxicity by Tissue/Organ

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

Graft vs Host Disease | Immune System Disorders

United States
Eisai Inc.

Completed

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

United States
Boston Scientific Corporation

Completed

Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF

Congestive Heart Failure

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States, Canada
Yale University
Eisai Inc.

Completed

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma

United States
Pharmacia

Completed

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

HIV Infections | Mycobacterium Avium-Intracellulare Infection

United States
University of Miami

Withdrawn

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
University of California, San Francisco
Washington University School of Medicine; Eisai Inc.

Terminated

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Peripheral T-Cell Lymphoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditions

United States
Mayo Clinic

Recruiting

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Adenocarcinoma | Clinical Stage IV Gastric Cancer AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Adenocarcinoma | Unresectable Pancreatic Carcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IIB Esophageal Cancer | Stage IIA Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Germ Cell Tumor | Stage III Testicular Cancer | Recurrent Malignant Testicular Germ Cell Tumor | Recurrent Extragonadal Seminoma | Recurrent Malignant Extragonadal Germ Cell Tumor | Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell... and other conditions

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Down Syndrome | Philadelphia Chromosome Positive | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia | Adult B Lymphoblastic Lymphoma | Ann Arbor Stage I B Lymphoblastic Lymphoma | Ann Arbor Stage... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Switzerland
National Cancer Institute (NCI)

Suspended

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome | Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia

Search clinical trials for: ONTAK (denileukin difitox, DAB389IL-2)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations